A long story for a short peptide: therapeutic efficacy of a cleavage-specific tau antibody

Giuseppina Amadoro¹, Valentina Latina, Pietro Calissano

**Tau is the prime participant in the Alzheimer’s disease (AD) neurodegeneration:** AD, the main cause of dementia in elderly people, is a multifactorial neurodegenerative disorder characterized by a long prodromal phase (starting more than two decades before clinical symptoms appear) with brain accumulation/misfolding of amyloid β (Aβ) in insoluble amyloid plaques and of tau protein in neurofibrillary tangles. Even though the slow-progressing clinical development of the disease opens important diagnostic and therapeutic perspectives for the preventive medicine, there’s a general consensus that the amyloid deposition reaches early a plateau and does not change over time. On the contrary, the tau pathology is tightly linked with synaptic deterioration and neuronal death which eventually lead to the manifestation of classical symptomatology (Jack et al., 2018). Indeed, several lines of evidence support the notion that alterations of tau homeostasis actually drive the neurodegeneration in human tauopathies, including the most common AD where no genetic mutation in microtubule associated protein tau (MAPT) has been reported up to now. To regard genetic, clinical and histopathological studies have undoubtedly shown that abnormalities in tau protein(s) are sufficient to cause, both in vitro and in vivo, synaptic dysfunction, motor/sensorimotor and cognitive deficits indicative of loss of selective vulnerable neuronal populations (Spillantini and Goedert, 2013). Secondly, compelling evidence have also demonstrated that tau proteins have necessary, not-dispensable role in Aβ-dependent neurodegeneration, both in cellular and animal AD models and in elderly individuals (Iqbal and Gong, 2016). Moreover, both the “amyloid-cascade hypothesis” (i.e. Aβ is the initial insult driving tau pathology) and the “dual hit-model” (i.e. tau pathology is independent of Aβ which just provokes the tau spread to neocortex), which have been proposed to explain the etiopathogenesis of AD, posit a crucial place (i.e. inducive and/or permissive) of tau pathobiology in the chains of events ending in synaptic derangement and irreversible loss of neuronal viability (Small and Duff, 2008). Consistently, tau pathology correlates much more strongly than Aβ pathology with neurodegeneration and cognitive impairment, both spatially and temporally. In fact, the amyloid deposition does not cause the pronounced synaptic and neuronal loss which typically characterize the progressive clinical course of AD. Finally, tau is a common downstream effector both in Aβ-dependent and -independent pathogenic mechanisms such as increased amyloid precursor protein (APP) gene dosage/APP-derived-C-Terminal fragment (CTF-C99), cholesterol metabolism/ endocytic, trafficking microglial immune activation, apolipoprotein E allele epsilon 4.

Collectively, these findings outline that removal of Aβ is not sufficient per se to improve brain function and that tau targeting can be more clinically relevant than Aβ-directed disease-modifying therapies for the AD cure, once the clinical symptoms become evident (Busche and Hyman, 2020).

**The N-terminal end of tau and its emerging contributing role in the AD onset and progression:** Tau is a soluble, highly flexible, intrinsically disordered protein which is predominantly expressed in the neurons where it binds and stabilizes the microtubules track. Tau primary structure includes three different regions designed as: (i) the N-terminal acidic projection domain (amino acids 1–150); (ii) the stretch of tau encompassing residues 151–243 (the proline-rich domain); (iii) the microtubule binding domain consisting of four imperfectly repeated motifs (R1–R4), separated by flanking regions, which together are devoted to interact with and promote the tubulin heterodimer assembly; (iv) the amino acids 370–441 forming the C-terminal tail. Historically, the interest of scientific community has been mainly drawn by the hexapeptide motifs (Paired Helical Filaments, PFHs) located in the R2 and R3 of tau. These short sequences exhibit a strong propensity to form ordered β-sheet structures and are proposed to be the core nucleation sites necessary for the intracellular self-assembly of tau into insoluble filaments, which usually characterize the neurofibrillary pathology of AD and other, non-AD human related tauopathies (Mandekow and Mandelkow, 2012). Recently however, a growing number of studies have highlighted the important role of N-terminal extremity provided with toxic properties such as misfolding/aggregation, activity-dependent synaptic release and cell-to-cell propagation of proteopathic seeds. To this regard, compelling evidence have demonstrated that the N-terminal projection domain of tau: (1) interacts with the plasma membrane and with molecules involved in signal transduction pathways; (2) undergoes early conformational changes and post-translational modifications in human tautopathies, including AD; (3) is prone to come into higher order of oligomerization and promote in cells the liquid-liquid phase separation, a mechanism along which droplets of disordered proteins undergo transition into aggregates; (4) is a mediator of Aβ-dependent and -independent synaptic dysfunction, acting both in pre- and post-synaptic compartments; (5) is preferentially secreted from synaptosomes of AD brains and in conditioned media from patient-derived induced pluripotent stem cell cortical neurons; (6) is largely detected in cerebrospinal fluid (CSF) and in plasma from AD and mild cognitive impairment patients. Besides, by measuring the phosphorylated tau at threonine-181 with an N-terminal partner antibody (N-phospho-tau181) in CSF and in plasma, recent strong data indicates this novel ptau biomarker markedly increases in preclinical AD when only subtle changes of Aβ pathology are evident, further stressing the clinical importance of specifically targeting the N-terminal tau family at very early stages in the disease development (Karikari et al., 2020; Suárez-Calvet et al., 2020). Taken together, these studies underlining the unexpected physiological role of the N-terminal extremity of tau provide the proof-of-concept that the not-microtubule bindings region of protein can be an attractive target for the cure of AD and, possibly, of other non-related human tauopathies (Polanco et al., 2018; Brandt et al., 2020).

**Antibody-mediated targeting of the N-terminal domain of tau is a valuable disease-therapy for AD:** At present, a large part of pharmacological and immunological approaches targeting A i.e. secretase inhibitors and anti-A antibodies), have failed to reach the final end-points of AD clinical trials, mainly due to the appearance of toxicity and/or the lack of efficacy (Giacobini and Gold, 2013). Therefore, alternative tau-based interventions have been attempted, including inhibition of kinases, targeting of aggregation, modulation of degradation, microtubule stabilization and passive or active immunotherapy relying on the antibody-mediated clearance of both intracellular and extracellular, deleterious tau species (Polanco et al., 2018). In contrast to active vaccination depending on the direct stimulation of immune response to develop antibodies, passive immunization is safer and more adaptable, being provided with a reduced risk of eliciting an adverse immune reaction. Besides, it also offers a great flexibility to target the epitopes profile changes which evolve over the disease progression. It is also worth mentioning that the tau antibodies are amenable for a proper selection of specific targeted epitopes and/or
their conformation(s) and are also endowed with ability of successfully penetrating the cerebral structures. Indeed, tau antibodies can partecipate to the elimination of toxic tau species by promoting their net efflux from brain parenchyma to peripheral CSF, following the "peripheral sink" route. Alternatively, it has been shown that tau antibodies can even cross the blood-brain barrier and be readily uptaken by neurons, promoting the intracellular sequestration of toxic forms of tau and/or preventing their extracellular secretion and spreading throughout the brain. Nevertheless, in order to develop an effective and safe tau-directed immunotherapy, the identification of the molecular identity (soluble versus prefibrillar/aggregated, full-length versus truncated, unmodified versus post-translational modified) or and/or nature (vesicular versus naked) of the neurotoxic forms to be targeted is only the first step. An ideal, antibody-mediated treatment should also provide the specific neutralization of these harmful species, in the absence of unwanted detrimental side-effects resulting from interference ("loss-of-function") with the normal physiological form of protein. Relevantly, tau protein has been recognized to deal into neurons with numerous important functions beyond the control of microtubule stability and dynamics (Sotropoulos et al., 2017). In this context, we have first identified and deeply characterized a fragment of 20–22 kDa molecular weight generated by aberrant truncation at D25 and R230 amino acids located in the N-terminal end of the longest human tau isoform (2N4R, 441 amino acids). By means of a comprehensive battery of biochemical, morphological and functional analyses, we found out that this short peptide (aka NH₂htau) turned out to be endowed with a potent "gain-of-function" action, for the most part centered on the synaptic compartments (Amadoro et al., 2020) (Figure 1A). In summary, we demonstrated that the NH₂htau is: (i) neurotoxic in mature hippocampal neurons, (ii) detected into cellular and animal AD models, (iii) expressed in human autopsic AD specimens mainly into the synaptic compartment(s) and in peripheral CSFs from patients affected by AD and other not-AD tauopathies; (iv) able to alter the normal synaptic function(s), both in vitro and in vivo. More recently, we have also developed a monoclonal antibody-named 12A12mAb (DRKD(25)-QGYYTMHQDE epitope, phosphorylation-independent state) which in vivo selectively neutralizes this harmful species(s) without altering the full-length normal tau. 12A12mAb, when intravenously (i.v.)-injected into 6-month-old transgenic AD animals (Tg2576 mice, APP KM670/671NL Swedish; 3XTg mice, APP Swedish/MAPT P301L/PSEN1 M146V), markedly alleviates the disease-associated signs, such as deficits in spatial memory and orientation, APP/...
AB and phosphoatau accumulation, loss in dendritic spine density in pyramidal CA1 neurons, electrophysiological deficits in hippocampal long-term potentiation at the CA3-CA1 synapses, reactive astro-microgliosis (Corsetti et al., 2020). Importantly, we found out that systemic delivery of 12A12mAb inhibits in vivo not only tau but also APP/AB pathology suggesting that a positive, feed-forward regulation occurs at AD synapses. APP/AB dysmetabolism is more likely to trigger into hypammocampal neurons the disease pathway via generation of truncated N-tau which, in turn, further increases the APP/AB levels in a self-propagating noxious cycle, which can be specifically antagonized by the cleavage-specific 12A12mAb (Figure 1B). It is worth noting that the action mechanism(s) of 12A12mAb appears not to require the engagement of microglia offering thus in vivo a potent neuroprotective effect without induction of the excessive harmful neuroinflammatory response which, on the contrary, often halts the current progression of the clinical trials enrolling the anti-AB antibodies. Thus, our preclinical findings prospect that tau-based immunotherapy via the “humanized” version of parental murine 12A12mAb (h12A12mAb) could be: (i) an effective (truncated tau-specific); (ii) safe (normal tau-preserving and, thus, without adverse potential side-effects); (iii) non-invasive potential disease-modifying therapy to contrast the AB-dependent and -independent cognitive deficits in human beings affected from AD and, possibly, other not-AD human tauopathies. It is worth noting that the anti-pan tau antibodies binding all forms of tau usually suffer from low availability of their effective dose in vivo (i.e., “target distraction” due to dilution of the antibody’s action between healthy/irrelevant and pathological tau forms). Conversely, anti-tau antibodies which selectively target/intercept the pathogenic tau species, such as the h12A12mAb, would avoid unproductive binding toward the normal protein with an increase of overall therapeutic efficacy within a fixed treatment period time and a parallel decrease of the potential undesired side-effects. In addition to the advantages offered in terms of reduction in antibody dosage and in time of treatment—which are extremely important especially in the medical care of chronic diseases such as AD which usually require prolonged medications and multiple/high dose administrations of drugs- h12A12mAb administration is awaited to exhibit an improved efficacy in comparison to other therapeutic tau antibodies when tested in future clinical trials in human beings. To this regard, combined interventions aimed at reducing concomitantly both AB and tau pathology are expected to increase the loss of neuronal connectivity and amnestic disabilities associated with clinical symptomatology of AD more powerfully than monotherapy altering either neuropathology alone. To this regard, it is widely recognized that AD has complex etiopathogenesis displaying numerous multifactorial and heterogeneous features which involve different, both intrinsic and extrinsic causative mechanisms (Busche and Hyman, 2020).

In view of these findings, we propose that early medical regimen with not-invasive and safe combined therapies aimed at reestablishing the homeostasis of both APP/AB and tau, such as that potentially offered by h12A12mAb, might significantly increase the clinical management of AD whose rapid increase in our aging societies is bound to reach over 150 million in 2050. Finally, as the retina and other ocular structures, which share similar characteristics to the central nervous system, are considered a “window to the brain”, h12A12mAb should be also evaluated as potential candidate tool to advance an early AD diagnosis of cerebral damage starting from inspection of patients’ eye.

The present work was supported by in part by Fondo Ordinario Enti (FOE D.M.865/2019) in the framework of a collaboration agreement between the Italian National Research Council and EBI (2019-2021) (to PC). VL was supported by Post-doctoral Fellowship by Operatori Sanitari Assistiti (OSA).

Giuseppina Amadoro*, Valentina Latina, Pietro Calissano Institute of Translational Pharmacology (IFT) – National Research Council (CNR), Via Fosso del Cavaliere 100, 00133-Rome, Italy (Amadoro G) European Brain Research Institute (EBI), Viale Regina Elena 295, 00161-Rome, Italy (Amadoro G, Latina V, Calissano P)
*Correspondence to: Amadoro Giuseppina, PhD, g.amadoro@innm.cnr.it. https://orcid.org/0000-0003-2080-2951 (Amadoro Giuseppina)

**Date of submission:** November 27, 2020
**Date of decision:** January 14, 2021
**Date of acceptance:** February 4, 2021
**Date of web publication:** April 23, 2021

https://doi.org/10.4103/1673-5374.313043

How to cite this article: Amadoro G, Latina V, Calissano P (2020) Non-terminal tau truncation in the pathogenesis of Alzheimer’s disease (AD): Developing a novel diagnostic and therapeutic approach. Biochim Biophys Acta Mol Basis Dis 1866:165584.

Brandt R, Trushina N, Bakota I (2020) Much more than a cytoskeletal protein: physiological and pathological functions of the non-microtubule binding region of Tau. Front Neurol 11:590059.

Busche MA, Hyman BT (2020) Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Neurosci 23:1183-1193.

Corsetti V, Borreca A, Lanza V, Giacovazzo G, Pignataro A, Kashia J, Natale F, Cocco S, Riaudino M, Malerba F, Florio R, Ciarpata R, Coccurello D, D’Amelio M, Ammassari-Teule M, Grassi C, Calissano P, Amadoro G (2020) Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models. Brain Commun 2:fcac039.

Giacobini E, Gold G (2013) Alzheimer disease therapy-moving from amyloid-β to tau. Nat Rev Neurol 9:677-686.

Iqbal K, Liu F, Gong CX (2016) Tau and neurodegenerative disease: the story so far. Nat Rev Neurol 12:155-27.

Jack CR Jr, Bennett DA, Blennow K, Dunn B, Haebeler SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Mollinuevo JL, Montine T, Phelps C, Raskin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, et al. (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535-562.

Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Naud M, Kang MS, Therriault J, Scholl M, Massarweh G, Soucy JP, Höglund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stormrud E, Zetterberg H, et al. (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19:422-433.

Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in neurofibrilloger degeneration. Cold Spring Harb Perspect Med 2:a006247.

Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Götz J (2018) Amyloid-β and tau complexity-towards improved biomarkers and targeted therapies. Nat Rev Neurol 14:22-39.

Small SA, Duff K (2008) Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuroen 60:534-542.

Sotropoulos I, Galas MC, Silva JM, Skoulakis E, Wegmann S, Maina MB, Blum D, Sayas CL, Mandelkow EM, Mandelkow E, Spillantini MG, Mandelkow E, Spillantini MG, Tironi I, Hohnjec M, Natale F, Rinaudo M, Buee L (2017) Atypical, non-standard functions of the microtubule associated Tau protein.Acta Neuropathol Commun 5:91.

Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12:609-622.

Suárez-Calvet M, Karikari TK, Cavaliere 100, 00133-Rome, Italy (Amadoro G, Latina V, Calissano P). The present work was supported by in part by Fondo Ordinario Enti (FOE D.M.865/2019) in the framework of a collaboration agreement between the Italian National Research Council and EBI (2019-2021) (to PC). VL was supported by Post-doctoral Fellowship by Operatori Sanitari Assistiti (OSA).